Page last updated: 2024-08-17

17-alpha-hydroxyprogesterone and Carcinoma in Situ

17-alpha-hydroxyprogesterone has been researched along with Carcinoma in Situ in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baffico, M; Cappi, C; De Cassan, P; Foppiani, L; Giusti, M; Lando, G; Minuto, F; Patrosso, MC; Penco, S; Vitali, A1

Other Studies

1 other study(ies) available for 17-alpha-hydroxyprogesterone and Carcinoma in Situ

ArticleYear
Bilateral carcinoma in situ of the testis and cystic fibrosis transmembrane conductance regulator (CFTR) mutation in an azoospermic patient with late-onset 21beta-hydroxylase deficiency.
    Journal of endocrinological investigation, 2004, Volume: 27, Issue:4

    Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; Adult; Carcinoma in Situ; Cystic Fibrosis Transmembrane Conductance Regulator; Dehydroepiandrosterone Sulfate; Dexamethasone; Follicle Stimulating Hormone; Glucocorticoids; Humans; Male; Mutation; Obesity; Oligospermia; Steroid 21-Hydroxylase; Testicular Neoplasms; Testosterone; Vas Deferens

2004